Elsie Biotechnologies
A private biopharmaceutical company developing oligonucleotide therapeutics by integrating discovery, development, and delivery to increase potency, decrease toxicity, and optimize delivery.
Elsie’s discovery platform accesses the entire oligonucleotide chemistry space to optimize current modalities in gene silencing and splice switching, and applies proprietary chemistry technologies to develop novel, diverse oligonucleotide therapeutics that are designed to be more potent, safer, and easier to deliver to target tissues.
Latest Elsie Biotechnologies News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze